Troglitazone Reduces Fibrosis in Retinal Cells
Author Information
Author(s): Cheng Huey-Chuan, Ho Tsung-Chuan, Chen Show-Li, Lai Huei-Yi, Hong Kuo-Fu, Tsao Yeou-Ping
Primary Institution: Mackay Memorial Hospital, Taipei, Taiwan
Hypothesis
Can troglitazone inhibit TGFβ2-mediated fibrosis in retinal pigment epithelial cells?
Conclusion
Troglitazone significantly prevents TGFβ2-induced fibrogenesis in retinal pigment epithelial cells by inhibiting Smad2 and Smad3 phosphorylation.
Supporting Evidence
- Troglitazone inhibited TGFβ2-induced collagen type I and fibronectin expression.
- Cell migration induced by TGFβ2 was significantly reduced by troglitazone treatment.
- Troglitazone prevented the phosphorylation of Smad2 and Smad3, which are important for TGFβ signaling.
Takeaway
Troglitazone is a drug that helps stop certain cells in the eye from becoming too fibrous and causing problems. It works by blocking some signals that would normally make these cells change.
Methodology
Human retinal pigment epithelial cells (ARPE-19) were treated with troglitazone and TGFβ2, and various assays were performed to measure collagen and fibronectin expression, cell migration, and Smad phosphorylation.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website